High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108023
Title:
High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study.
Authors:
Gomm, S A; Thatcher, Nick; Cuthbert, A; Chang, James; Burmester, H; Hall, P; Carroll, K B
Abstract:
Twenty-three patients with advanced NSCLC were treated with high dose chemotherapy using four agents and autologous bone marrow reinfusion. Ten patients received two bolus doses of cyclophosphamide (maximum tolerated total dose 10 G m-2), ifosfamide as a 24 h infusion (11 G m-2) followed by mitomycin C (70 mg m-2) as a subsequent 24 h infusion and mustine as two boluses (total dose 30 mg m-2). Another 13 patients received the same agents except cisplatin was substituted for cyclophosphamide, two doses (total dose 100 mg m-2) being given in a 24 h period. The median time of recovery to greater than or equal to 20,000 platelets was 21 days and of neutropaenia greater than or equal to 500 was 12-15 days. Unusual non-haematological toxicity e.g. cardiomyopathy, colitis, veno occlusive disease was not noted, all patients being given regular selenium and other trace elements. Three patients died in the first 2 weeks. There were five complete responses (22%) and 12 partial responses (52%) with four patients (2CR, 2PR) still alive at 27, 48, 73 and 82 weeks. The patient's Karnofsky performance in the cisplatin regimen improved over pretreatment values when compared a month after the end of treatment. The high dose regimen was associated with a high (74%) response rate, but with an overall median survival of only 6 months. The regimen has no advantage over conventional doses with the same agents in patients with metastatic NSCLC.
Affiliation:
Department of Thoracic Medicine, Wythenshawe Hospital, Manchester, UK.
Citation:
High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study. 1991, 63 (2):293-7 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Feb-1991
URI:
http://hdl.handle.net/10541/108023
PubMed ID:
1847648
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorGomm, S Aen
dc.contributor.authorThatcher, Nicken
dc.contributor.authorCuthbert, Aen
dc.contributor.authorChang, Jamesen
dc.contributor.authorBurmester, Hen
dc.contributor.authorHall, Pen
dc.contributor.authorCarroll, K Ben
dc.date.accessioned2010-07-21T08:31:26Z-
dc.date.available2010-07-21T08:31:26Z-
dc.date.issued1991-02-
dc.identifier.citationHigh dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study. 1991, 63 (2):293-7 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid1847648-
dc.identifier.urihttp://hdl.handle.net/10541/108023-
dc.description.abstractTwenty-three patients with advanced NSCLC were treated with high dose chemotherapy using four agents and autologous bone marrow reinfusion. Ten patients received two bolus doses of cyclophosphamide (maximum tolerated total dose 10 G m-2), ifosfamide as a 24 h infusion (11 G m-2) followed by mitomycin C (70 mg m-2) as a subsequent 24 h infusion and mustine as two boluses (total dose 30 mg m-2). Another 13 patients received the same agents except cisplatin was substituted for cyclophosphamide, two doses (total dose 100 mg m-2) being given in a 24 h period. The median time of recovery to greater than or equal to 20,000 platelets was 21 days and of neutropaenia greater than or equal to 500 was 12-15 days. Unusual non-haematological toxicity e.g. cardiomyopathy, colitis, veno occlusive disease was not noted, all patients being given regular selenium and other trace elements. Three patients died in the first 2 weeks. There were five complete responses (22%) and 12 partial responses (52%) with four patients (2CR, 2PR) still alive at 27, 48, 73 and 82 weeks. The patient's Karnofsky performance in the cisplatin regimen improved over pretreatment values when compared a month after the end of treatment. The high dose regimen was associated with a high (74%) response rate, but with an overall median survival of only 6 months. The regimen has no advantage over conventional doses with the same agents in patients with metastatic NSCLC.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdult-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshBone Marrow Transplantation-
dc.subject.meshCarcinoma, Non-Small-Cell Lung-
dc.subject.meshCisplatin-
dc.subject.meshCyclophosphamide-
dc.subject.meshDrug Evaluation-
dc.subject.meshHumans-
dc.subject.meshIfosfamide-
dc.subject.meshLung Neoplasms-
dc.subject.meshMechlorethamine-
dc.subject.meshMiddle Aged-
dc.subject.meshMitomycin-
dc.subject.meshMitomycins-
dc.subject.meshSurvival Rate-
dc.subject.meshTransplantation, Autologous-
dc.titleHigh dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II study.en
dc.typeArticleen
dc.contributor.departmentDepartment of Thoracic Medicine, Wythenshawe Hospital, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.